Suchandrima Bhowmik

Feature Writer

M.Sc. Microbiology

Suchandrima has a Bachelor of Science (B.Sc.) degree in Microbiology and a Master of Science (M.Sc.) degree in Microbiology from the University of Calcutta, India. The study of health and diseases was always very important to her. In addition to Microbiology, she also gained extensive knowledge in Biochemistry, Immunology, Medical Microbiology, Metabolism, and Biotechnology as part of her master's degree.

Suchandrima is also an avid writer and has written for some reputable Indian organizations. However, she decided to pursue scientific writing as it would be the best combination of what she loves, research and writing. Additionally, she authored a book chapter that was published in Elsevier.

Currently she is also working as a medical writer where she has to develop articles for several diseases and also provide detailed descriptions of medicines and other associated products.

She is very enthusiastic about working at AzoNetwork's medical website, News Medical, since it will keep her updated about the latest breakthroughs in medical and health science that are happening around the world.

Apart from science, her hobbies include reading and painting. She has an art page on Instagram with over 1k followers and plans not to lose touch with her hobbies. She loves reading novels, the last novel she read was Men without Women by Haruki Murakami.

See less

Articles from Suchandrima

In UK's 1st wave, 10% of COVID infections were acquired in hospitals

Their study published in The Lancet journal involved assessing the magnitude of hospital-acquired COVID-19 in the case of acute and long-term National Health Service (NHS) hospital facilities in the UK during the first wave of the pandemic.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Role of neutrophil-epithelial interactions in SARS-CoV-2 infection

Researchers discuss the relationship between airway neutrophils and SARS-CoV-2 infection to determine the impact that neutrophils have on COVID-19.

15 Aug 2021

Utah warns of Delta variant eroding COVID vaccine effectiveness

A recent study finds a reduction in vaccine effectiveness against COVID-19 in Utah corresponding to the spread of the Delta variant in the region.

15 Aug 2021

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

A study measured neutralization of SARS-CoV-2 and vaccine responses in immunocompromised patients with systemic inflammatory diseases.

11 Aug 2021

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

In the current study, the authors evaluate several different competitive ELISAs that could be used to measure serum antibodies.

11 Aug 2021

Cardioprotective role of HIF1α in COVID-19 patients

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first emerged in Wuhan, China, in late December 2019, has quickly become the most urgent issue facing scientists worldwide. It has been reported that the respiratory infection causes cardiac dysfunction in 25-55% patients, including hospitalized patients and non-critical patients.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

In addition to clinical trials conducted to determine the safety and efficacy of the mRNA vaccines, additional studies began describing the serological response to the vaccines under "real-world" conditions, especially with the onset of the SARS-CoV-2 variants and case reports of vaccine escape.

9 Aug 2021